drugset

drugset / Trial / NCT05815186

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NCT05815186 ↗

Phase 2 Withdrawn NYU Langone Health

NaSingle-groupOpen-labelTreatment

Summary

Study record has been combined with NCT05815173. See NCT05815173 for summary.

Timeline

Start: 2024-04
Primary completion: 2025-04
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ladarixin	Unknown	—	—
Subject	Sotorasib	Small molecule	960 mg	Oral

Indications